What is Tesamorelin?
Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing factor (GRF), specifically the full 44-amino-acid sequence (GRF 1-44) with a trans-3-hexenoic acid modification at the N-terminus. This structural modification confers enhanced resistance to dipeptidyl peptidase IV (DPP-IV) degradation — the primary enzyme responsible for rapid inactivation of native GHRH in circulation — substantially extending the peptide's effective plasma half-life.
As a GHRH receptor agonist, tesamorelin stimulates pituitary somatotropes to release GH through the same receptor pathway as endogenous GHRH, making it one of the most physiologically faithful GHRH analogues available for research. Unlike shorter GHRH fragments (such as the 1-29 basis of CJC-1295), tesamorelin retains the full native GRF sequence and therefore the complete receptor binding domain.
ClaraScience supplies tesamorelin in 10mg lyophilised vials independently HPLC-tested to ≥99.0% purity (99.13% verified this batch). For laboratory research use only.
Structure. Full GRF 1-44 sequence (44 amino acids) with trans-3-hexenoic acid N-terminal modification for DPP-IV resistance.
Clinical stage. Phase III trials completed. Approved in some markets as Egrifta™ for HIV-associated lipodystrophy.
Research value. Full-length GHRH analogue for GH axis research, more physiologically faithful than shorter GHRH fragments.
Research Background
Tesamorelin's clinical development was focused primarily on HIV-associated lipodystrophy, where antiretroviral therapy commonly induces visceral adipose accumulation alongside metabolic dysregulation. The pivotal Phase III data was published by Falutz et al. in the New England Journal of Medicine (2007), demonstrating statistically significant reductions in visceral adipose tissue assessed by CT scan in HIV-infected patients with lipodystrophy over 26 weeks.
Tesamorelin received FDA approval in 2010 as Egrifta™ (Theratechnologies) for the treatment of excess abdominal fat in HIV-infected adults with lipodystrophy — making it the only GHRH analogue to achieve regulatory approval for any indication. This clinical history provides an unusually well-characterised human pharmacokinetic and safety dataset that supports its use as a research reference compound.
In preclinical research, tesamorelin serves as a useful tool for studying GHRH receptor pharmacology, GH axis dynamics, and the metabolic consequences of pulsatile GH stimulation in animal models. It is distinguished from shorter GHRH fragments like CJC-1295 No DAC by its full 44-amino-acid sequence and established clinical data package.
Key citation Falutz J et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." N Engl J Med. 2007;357(23):2359–2370.
Compound Specifications
| Common Name |
Tesamorelin (GRF 1-44 analogue) |
| Structure |
44 amino acids · trans-3-hexenoic acid N-terminal modification |
| Molecular Weight |
5135.89 g/mol |
| Receptor Target |
GHRH receptor (pituitary) |
| Purity (HPLC) |
≥99.0% (99.13% verified this batch) |
| Vial Size |
10mg lyophilised powder |
| Storage |
2–8°C (short-term) · −20°C (long-term) |
| Primary Reference |
Falutz et al., N Engl J Med 2007;357:2359–2370 |
Storage & Handling
- Unopened vial: 2–8°C for regular use; −20°C for longer-term storage.
- Reconstituted: 2–8°C, use within 28 days. No freeze-thaw after reconstitution.
- Reconstitution: Sterile bacteriostatic water. Use our free reconstitution calculator.
Full protocols in our Storage & Handling Guide.
Ordering & Pricing — Australia
| Quantity |
Price per vial |
Saving |
| 1–4 vials |
$139.95 AUD |
— |
| 5–9 vials |
$129.95 AUD |
Save 7% |
| 10+ vials |
$119.95 AUD |
Save 14% |
Free priority tracked shipping on orders over $250 AUD. 24-hour dispatch. Wholesale enquiries welcome.
Frequently Asked Questions
What is tesamorelin?
Tesamorelin is a synthetic GRF 1-44 analogue (44 amino acids) with a trans-3-hexenoic acid modification for DPP-IV resistance. It acts as a GHRH receptor agonist, stimulating pituitary GH secretion. Phase III data exists for visceral adiposity reduction. For laboratory research use only.
Is tesamorelin approved anywhere?
Tesamorelin is approved in the USA and Canada as Egrifta™ for HIV-associated lipodystrophy. It is not approved by the TGA in Australia for therapeutic use. ClaraScience supplies it as a research-grade compound for laboratory research only.
What is the difference between tesamorelin and CJC-1295?
CJC-1295 No DAC is based on the shorter GHRH 1-29 fragment with four amino acid substitutions for DPP-IV resistance. Tesamorelin is the full GRF 1-44 sequence (44 amino acids) with an N-terminal trans-3-hexenoic acid modification. Tesamorelin is closer to native GHRH in sequence and has undergone Phase III clinical evaluation.
Is tesamorelin available in Australia?
ClaraScience stocks tesamorelin in our Australian warehouse. 10mg vials, research-grade, dispatched within 24 hours. For laboratory research use only.
